Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort

Department of Community Medicine 8 Health Care, University of Connecticut Health Center, Farmington, CT, 06030.
International Journal of Cancer (Impact Factor: 5.09). 04/2014; 134(8). DOI: 10.1002/ijc.28504
Source: PubMed


Several prospective studies suggest that C-Reactive Protein (CRP), a non-specific serologic marker of inflammation, might be linked to risk of colorectal cancer (CRC) whereas others have reported null or protective effects. We analyzed data from 7,072 participants (50yrs-85yrs) in the U.S. National Health and Nutrition Examination Survey III (1988-94), a nationally representative cohort (n=33,994; 2m-85 yrs) with vital status follow-up to 2000. Hazard Ratios (HR) for mortality associated with baseline Clinically-Raised (≥ 1.00 mg/dL) and Intermediate (≥ 0.22 to 0.99 mg/dL) CRP levels were estimated using Cox Proportional Hazards Regression controlling for CRC risk factors. There were 59 deaths from CRC, 106 from Other Obesity-Related Cancers (Other-ORC), 1130 from Cardiovascular Disease (CVD). Participants with Clinically-Raised CRP at baseline were found to have a statistically significant greater risk of CRC death (HRs=2.36 to 2.47) in comparison to persons with undetected levels. HRs were lower for death from Other-ORC and CVD (1.82, 95% CI 1.05-3.15; 1.53, 95% CI 1.29-1.81; respectively). Intermediate CRP level was associated with a non-significant 10% to 21% increased risk for CRC death. HR for CRC death was higher among persons with a normal BMI (2.16, 95% 0.96-4.87, P=0.06) compared to those who were overweight (1.22, 95% CI 0.53-2.78) or obese (1.23, 95% CI, 0.37-4.08). A similar pattern was observed for Waist Circumference. This effect modification suggests that the impact of chronic inflammation may be independent of excess body fat. Future research is recommended to confirm emerging data that elevated serologic CRP might reflect underlying colonic inflammation. © 2013 Wiley Periodicals, Inc.

18 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose Prolong inflammation is a central process observed in several chronic conditions and may be responsible for survival. There is an increasing evidence showing the role of diet in inflammation and habitual diet may be responsible for low-grade inflammation. The purpose of our study was to assess the effect of inflammatory properties of habitual diet measured by the Dietary Inflammatory Index (DII) on survival among surgical patients treated for colorectal cancer (CRC). Methods A follow-up study among 689 CRC patients (mean age 58 years, ±8.9; 56.7 % males) treated surgically was performed in Krakow, Poland. Habitual diet was assessed by a standardized semiquantitative food frequency questionnaire. Next, 23 dietary items were used to calculate DIIs. Vital records were verified to determine status of the participants. Results Study has shown linear association between DII and survival time among CRC patients with totally removed cancer treated by chemotherapy (b = −0.13, p = 0.024). After adjustment for several important covariates, DII was associated with survival during up to 3 years after surgery, but only in patients without distant metastases (3-year HRDII>−2.27 = 0.61, 95 % CI 0.38–0.99). Conclusions The results of the investigation have shown the usefulness of the DII as a potential predictor of survival among patients without distant metastases treated surgically for CRC.
    Journal of Cancer Research and Clinical Oncology 05/2014; 140(9). DOI:10.1007/s00432-014-1711-6 · 3.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: C-reactive protein (CRP) is involved in a wide range of diseases. It is a powerful marker for inflammatory processes used for diagnostic and monitoring purposes. We aimed to establish reference values as data on the distribution of serum CRP levels in young European children are scarce. Subjects: Reference values of high-sensitivity CRP concentrations were calculated for 9855 children aged 2.0-10.9 years, stratified by age and sex. The children were recruited during the population-based European IDEFICS study (Identification and prevention of Dietary- and lifestyle-induced health Effects in Children and infantS) with 18 745 participants recruited from 2007 to 2010. Results: In 44.1% of the children, CRP values were below or equal the detection limit of 0.2 mg/l. Median CRP concentrations showed a slight negative age trend in boys and girls, whereas serum CRP values were slightly higher in girls than in boys across all age groups. Conclusions: Our population-based reference values of CRP may guide paediatric practice as elevated values may require further investigation or treatment. Therefore, the presented reference values represent a basis for clinical evaluation and for future research on risk assessment of diseases associated with increased CRP levels among children.
    International journal of obesity (2005) 09/2014; 38 Suppl 2:S26-31. DOI:10.1038/ijo.2014.132 · 5.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Present review article highlights various cardiovascular risk prediction biomarkers by incorporating both traditional risk factors to be used as diagnostic markers and recent technologically generated diagnostic and therapeutic markers. This paper explains traditional biomarkers such as lipid profile, glucose, and hormone level and physiological biomarkers based on measurement of levels of important biomolecules such as serum ferritin, triglyceride to HDLp (high density lipoproteins) ratio, lipophorin-cholesterol ratio, lipid-lipophorin ratio, LDL cholesterol level, HDLp and apolipoprotein levels, lipophorins and LTPs ratio, sphingolipids, Omega-3 Index, and ST2 level. In addition, immunohistochemical, oxidative stress, inflammatory, anatomical, imaging, genetic, and therapeutic biomarkers have been explained in detail with their investigational specifications. Many of these biomarkers, alone or in combination, can play important role in prediction of risks, its types, and status of morbidity. As emerging risks are found to be affiliated with minor and microlevel factors and its diagnosis at an earlier stage could find CVD, hence, there is an urgent need of new more authentic, appropriate, and reliable diagnostic and therapeutic markers to confirm disease well in time to start the clinical aid to the patients. Present review aims to discuss new emerging biomarkers that could facilitate more authentic and fast diagnosis of CVDs, HF (heart failures), and various lipid abnormalities and disorders in the future.
Show more